+

WO2003006687A3 - Nouveaux genes cibles concernant des maladies cardiaques - Google Patents

Nouveaux genes cibles concernant des maladies cardiaques Download PDF

Info

Publication number
WO2003006687A3
WO2003006687A3 PCT/EP2002/007704 EP0207704W WO03006687A3 WO 2003006687 A3 WO2003006687 A3 WO 2003006687A3 EP 0207704 W EP0207704 W EP 0207704W WO 03006687 A3 WO03006687 A3 WO 03006687A3
Authority
WO
WIPO (PCT)
Prior art keywords
genes
heart
diseases
cardiomyopathy
relates
Prior art date
Application number
PCT/EP2002/007704
Other languages
English (en)
Other versions
WO2003006687A2 (fr
Inventor
Birgit Reuner
Daniela Bunk
Thomas Henkel
Original Assignee
Medigene Ag
Birgit Reuner
Daniela Bunk
Thomas Henkel
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medigene Ag, Birgit Reuner, Daniela Bunk, Thomas Henkel filed Critical Medigene Ag
Publication of WO2003006687A2 publication Critical patent/WO2003006687A2/fr
Publication of WO2003006687A3 publication Critical patent/WO2003006687A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne une variété de gènes présentant une expression anormale dans le tissu cardiaque, ainsi que des fragments de ces gènes. On peut utiliser l'évaluation du niveau d'expression de ces gènes afin de vérifier la prédisposition de mammifères et, de préférence, d'humains à une maladie cardiaque ou à un état aigu de ce type de maladie. Les maladies indiquées à titre préférentiel consistent en l'insuffisance cardiaque globale, la cardiomyopathie avec dilatation, la cardiomyopathie hypertrophique et la cardiomyopathie ischémique. L'invention concerne, de plus, des procédés servant à identifier des composés pouvant normaliser le niveau d'expression de ces gènes ou d'autres gènes affectés par cette expression anormale. On peut utiliser les composés identifiés afin de formuler des compositions, de préférence, des compositions pharmaceutiques permettant de traiter ces maladies à titre prophylactique ou thérapeutique. On peut également les utiliser en tant que composés précurseurs pour le développement de médicaments présentant une efficacité améliorée, une demi-vie prolongée, une toxicité limitée et les mettre en application pour traiter des maladies cardiaques. L'invention concerne également des procédés de thérapie génique somatique comparant l'introduction d'au moins une copie fonctionnelle d'un gène parmi les gènes mentionnés dans une cellule appropriée. Elle concerne enfin des animaux transgéniques non humains comprenant au moins un de ces gènes dans leur lignée germinale. On peut utiliser ces animaux transgéniques afin de développer des médicaments servant à traiter des maladies cardiaques.
PCT/EP2002/007704 2001-07-10 2002-07-10 Nouveaux genes cibles concernant des maladies cardiaques WO2003006687A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US30438501P 2001-07-10 2001-07-10
US60/304,385 2001-07-10

Publications (2)

Publication Number Publication Date
WO2003006687A2 WO2003006687A2 (fr) 2003-01-23
WO2003006687A3 true WO2003006687A3 (fr) 2003-08-28

Family

ID=23176292

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2002/007704 WO2003006687A2 (fr) 2001-07-10 2002-07-10 Nouveaux genes cibles concernant des maladies cardiaques

Country Status (1)

Country Link
WO (1) WO2003006687A2 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005078452A1 (fr) 2004-02-05 2005-08-25 Medtronic, Inc. Methodes et appareil permettant d'identifier des patients presentant un risque de developper des arythmies mettant leur vie en danger
US7608458B2 (en) 2004-02-05 2009-10-27 Medtronic, Inc. Identifying patients at risk for life threatening arrhythmias
US8027791B2 (en) 2004-06-23 2011-09-27 Medtronic, Inc. Self-improving classification system
US8335652B2 (en) 2004-06-23 2012-12-18 Yougene Corp. Self-improving identification method
WO2008053358A2 (fr) * 2006-07-25 2008-05-08 Deutsches Krebsforschungszentrum Signature d'une expression de gène commune dans une cardiomyopathie dilatée

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999024571A2 (fr) * 1997-11-10 1999-05-20 Curagen Corporation Genes a expression differentielle en cas d'hypertrophie cardiaque et leur utilisation a des fins de diagnostic et de traitement
WO1999036522A1 (fr) * 1998-01-19 1999-07-22 Shanghai Second Medical University Gene a faible similitude avec la tropomyosine (cbcadb07)
WO2000000506A2 (fr) * 1998-06-26 2000-01-06 Sagami Chemical Research Center Proteines humaines possedant des domaines hydrophobes et adn codant ces proteines
WO2000011942A1 (fr) * 1998-09-01 2000-03-09 Gene Logic, Inc. Identification d'un adn complementaire associe a l'ischemie dans le tissu cardiaque humain
WO2000032221A2 (fr) * 1998-12-01 2000-06-08 Genentech, Inc. Promotion et inhibition de l'angiogenese et de la vascularisation cardiaque
WO2000053753A2 (fr) * 1999-03-08 2000-09-14 Genentech, Inc. Activation ou inhibition de l'angiogenese et de la cardiovascularisation

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999024571A2 (fr) * 1997-11-10 1999-05-20 Curagen Corporation Genes a expression differentielle en cas d'hypertrophie cardiaque et leur utilisation a des fins de diagnostic et de traitement
WO1999036522A1 (fr) * 1998-01-19 1999-07-22 Shanghai Second Medical University Gene a faible similitude avec la tropomyosine (cbcadb07)
WO2000000506A2 (fr) * 1998-06-26 2000-01-06 Sagami Chemical Research Center Proteines humaines possedant des domaines hydrophobes et adn codant ces proteines
WO2000011942A1 (fr) * 1998-09-01 2000-03-09 Gene Logic, Inc. Identification d'un adn complementaire associe a l'ischemie dans le tissu cardiaque humain
WO2000032221A2 (fr) * 1998-12-01 2000-06-08 Genentech, Inc. Promotion et inhibition de l'angiogenese et de la vascularisation cardiaque
WO2000053753A2 (fr) * 1999-03-08 2000-09-14 Genentech, Inc. Activation ou inhibition de l'angiogenese et de la cardiovascularisation

Non-Patent Citations (12)

* Cited by examiner, † Cited by third party
Title
DATABASE EBI [online] EMBL; 20 September 1999 (1999-09-20), HE, K. ET AL.: "Human CBCADB07 polypeptide encoding cDNA", XP002231546, retrieved from EMBL accession no. AAX82075 Database accession no. AAX82075 *
DATABASE EBI [online] EMBL; 20 September 1999 (1999-09-20), HE, K.: "CBCADB07", XP002220905, retrieved from EMBL accession no. AAY17299 Database accession no. AAY17299 *
DATABASE EBI [online] EMBL; 22 July 1998 (1998-07-22), MAO, M. ET AL.: "Homo sapiens unknown mRNA, complete cds.", XP002231547, retrieved from EBI accession no. AF047439 Database accession no. AF047439 *
DATABASE EBI [online] EMBL; 28 February 2001 (2001-02-28), ASHKENAZI, A.J. ET AL.: "Human angiogenesis-associated protein PRO195 cDNA, SEQ ID NO:45", XP002231545, retrieved from EBI accession no. AAC97400 Database accession no. AAC97400 *
DATABASE EBI [online] EMBL; 28 February 2001 (2001-02-28), ASHKENAZI, A.J. ET AL.: "Human angiogenesis-associated protein PRO195, SEQ. ID. NO: 46.", XP002220904, retrieved from EMBL accession no. AAB53073 Database accession no. AAB53073 *
DATABASE EBI [online] EMBL; 7 November 2000 (2000-11-07), ASHKENAZI, A.J. ET AL.: "Human PRO195 protein sequence SEQ. ID. NO. 31", XP002220906, retrieved from EMBL accession no. AAB24394 Database accession no. AAB24394 *
DATABASE EBI [online] EMBL; 8 February 2001 (2001-02-08), ASHKENAZI, A.J. ET AL.: "Human PRO195 (UNQ169) protein sequence SEQ. ID. NO. 330", XP002220907, retrieved from EMBL accession no. AAB44289 Database accession no. AAB44289 *
DATABASE EBI [online] EMBL; 9 May 2000 (2000-05-09), KATO, S., KIMURA, T.: "Hydrophobic domain containing protein clone HP10349", XP002220908, retrieved from EMBL accession no. AAY78804 Database accession no. AAY78804 *
KNOELL R ET AL: "CHARACTERIZATION OF DIFFERENTIALLY EXPRESSED GENES FOLLOWING BRIEF CARDIAC ISCHEMIA", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, ACADEMIC PRESS INC. ORLANDO, FL, US, vol. 221, 16 April 1996 (1996-04-16), pages 402 - 407, XP002051684, ISSN: 0006-291X *
LATIF N ET AL: "Frequency and specificity of antiheart antibodies in patients with dilated cardiomyopathy detected using SDS-PAGE and western blotting.", JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY. UNITED STATES 1 NOV 1993, vol. 22, no. 5, 1 November 1993 (1993-11-01), pages 1378 - 1384, XP008010596, ISSN: 0735-1097 *
MAO, MAO ET AL.: "Identification of genes expressed in human CD34+ hematopoietic stem/progenitor cells by expressed sequence tags and efficient full-length cDNA cloning", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, vol. 95, no. 14, 7 July 1998 (1998-07-07), pages 8175 - 8180, XP002997332, DOI: doi:10.1073/pnas.95.14.8175 *
REDWOOD C S ET AL: "Functional effects of hypertrophic cardiomyopathy mutations in alpha-tropomyosin on Ca2+ regulation of thin filaments.", BIOPHYSICAL JOURNAL, vol. 74, no. 2 PART 2, February 1998 (1998-02-01), Forty-second Annual Meeting of the Biophysical Society;Kansas City, Missouri, USA; February 22-26, 1998, pages A354, XP008010594, ISSN: 0006-3495 *

Also Published As

Publication number Publication date
WO2003006687A2 (fr) 2003-01-23

Similar Documents

Publication Publication Date Title
WO2001092567A3 (fr) Nouveau genes cibles pour les maladies du coeur
Chomyn et al. MtDNA mutations in aging and apoptosis
Desler et al. Is there a link between mitochondrial reserve respiratory capacity and aging?
Richter Oxidative damage to mitochondrial DNA and its relationship to ageing
Wong et al. Copper chaperone for superoxide dismutase is essential to activate mammalian Cu/Zn superoxide dismutase
US20070248590A1 (en) Modulators of CDC2-like kinases (CLKS) and methods of use thereof
Melis et al. The role of XPC: implications in cancer and oxidative DNA damage
Zeviani et al. Mitochondrial disorders
Mustafi et al. Inflammatory priming predisposes mice to age-related retinal degeneration
Krishnan et al. Mitochondrial DNA mutations and aging
Gass et al. Progranulin: an emerging target for FTLD therapies
NO20055314D0 (no) 1,2,4-oksadiazolbenzosyreforbindelser og deres anvendelse for nonsense supresjon og behandling av sykdom
Barnes et al. SIN3 is critical for stress resistance and modulates adult lifespan
WO2000073764A3 (fr) Compositions et methodes pour l'utilisation therapeutique d'une sequence associee au gene atonal dans le traitement de la surdite, de l'osteoarthrite et d'une proliferation cellulaire anormale
BRPI0510206A (pt) método de identificação de fenótipo, célula isolada, métodos de identificação de agentes, agentes, agentes terapêuticos, método de avaliação de agente terapêutico, composição farmacêutica, métodos de tratamento, prevenção ou melhoria de disfunções e métodos de modulação
Jo et al. Therapeutic adenine base editing corrects nonsense mutation and improves visual function in a mouse model of Leber congenital amaurosis
WO2003006687A3 (fr) Nouveaux genes cibles concernant des maladies cardiaques
KR20210113606A (ko) 신경 질환을 검출, 예방, 회복 및 치료하는 방법
NO20020470L (no) Polymorfismer i det humane MDR-1 genet og deres diagnostiske og terapeutiske anvendelse
TWI221902B (en) Mitochondrial DNA damage as a predictor of coronary atherosclerotic heart disease
Malinow et al. Forward genetic screening identifies novel roles for N-terminal acetyltransferase C and histone deacetylase in C. elegans development
NO20021147D0 (no) Polymorfismer i det humane hPXR-genet og deres anvendelse i diagnostiske og terapeutiske applikasjoner
Li et al. Increased ROS generation and SOD activity in heteroplasmic tissues of transmitochondrial mice with A3243G mitochondrial DNA mutation
WO2003047532A3 (fr) Compositions et methodes destinees a l'utilisation therapeutique d'une sequence associee au gene atonal pour une maladie gastro-intestinale
Słodki et al. Mitochondrial theory of skeletal muscle ageing–new facts, new doubts

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载